JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

Search

Erasca Inc

Gesloten

1.47 5

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

1.4

Max

1.49

Belangrijke statistieken

By Trading Economics

Inkomsten

1.3M

-31M

Werknemers

103

EBITDA

-750K

-36M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+203.57% upside

Dividenden

By Dow Jones

Volgende Winsten

15 aug 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

2.8M

397M

Vorige openingsprijs

-3.53

Vorige sluitingsprijs

1.47

Technische score

By Trading Central

Vertrouwen

Bearish Evidence

Erasca Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

11 aug 2025, 17:49 UTC

Belangrijke Marktbewegers

180 Life Sciences Stock Jumps on $156 Million Notes Sale

11 aug 2025, 17:18 UTC

Belangrijke Marktbewegers

Tiziana Life Sciences Rises After FDA Approves IND for Foralumab Trial

11 aug 2025, 16:25 UTC

Winsten

Correction to Constellation Software 2Q Revenue Rises, Profit Shrinks Article on Aug. 8

11 aug 2025, 23:50 UTC

Marktinformatie

Nikkei May Rise as Yen Weakens -- Market Talk

11 aug 2025, 23:42 UTC

Marktinformatie

Global Energy Roundup: Market Talk

11 aug 2025, 23:42 UTC

Marktinformatie

Woodside's Share Price Implies Lofty Oil Price -- Market Talk

11 aug 2025, 23:36 UTC

Marktinformatie

Gold Edges Higher on Likely Technical Recovery -- Market Talk

11 aug 2025, 23:32 UTC

Marktinformatie

Argosy's New Bull Sees Sentiment Toward REITs Improving -- Market Talk

11 aug 2025, 23:02 UTC

Marktinformatie

RBA Set to Lower OCR With New Forecasts in Focus -- Market Talk

11 aug 2025, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

11 aug 2025, 20:37 UTC

Winsten
Acquisities, Fusies, Overnames

Bakkt Holdings: Andy Main Will Step Dn as Co-CEO and Director, Effective Aug 11, and Akshay Naheta Will Assume Role of CEO >BKKT

11 aug 2025, 20:37 UTC

Winsten
Acquisities, Fusies, Overnames

Bakkt Holdings 2Q Rev $577.9M >BKKT

11 aug 2025, 20:37 UTC

Winsten
Acquisities, Fusies, Overnames

Bakkt Holdings: In Upcoming Qtr, Will Conduct Comprehensive Review of Cost Structure to Ensure We Are Optimized, Driving Synergies Across Business, and Accelerating Path to Profitability >BKKT

11 aug 2025, 20:22 UTC

Winsten

Exodus Movement: Assets 2,058 Units of Bitcoin Valued at $220.5M, 2,729 Units of Ether Valued at $6.8M, $58.1M in Cash and Cash Equivalents, USD Coin, Treasury Bills as of June 30 >EXOD

11 aug 2025, 20:22 UTC

Winsten

Exodus Movement: Monthly Active Users 1.5M at End 2Q, Unchanged From 1.5M as of June 30, 2024 >EXOD

11 aug 2025, 20:22 UTC

Winsten

Exodus Movement: Processed Volume $1.38B in 2Q Dn 37% From 1Q, Bitcoin, Tether (TRX Network), Tether (ETH Network), USDC, SOL Top Assets Traded in 2Q >EXOD

11 aug 2025, 20:22 UTC

Winsten

Exodus Movement: Digital Assets and Liquid Assets $291.2M >EXOD

11 aug 2025, 20:22 UTC

Winsten

Exodus Movement 2Q Rev $25.8M >EXOD

11 aug 2025, 20:14 UTC

Marktinformatie

Canada Dollar Faces Near-Term Weakness on Trade Row, September Rate-Cut Chatter -- Market Talk

11 aug 2025, 19:12 UTC

Marktinformatie

Crude-Oil Futures Edge Up in Rangebound Trade -- Market Talk

11 aug 2025, 18:56 UTC

Marktinformatie

U.S. Natural-Gas Futures Fall on Forecast Loss of Late August Heat -- Market Talk

11 aug 2025, 18:31 UTC

Marktinformatie

Mining Halt Could Lift Lithium Prices in Near Term -- Market Talk

11 aug 2025, 17:43 UTC

Marktinformatie

Freeport-McMoRan Can Push Up Prices, Profits With Copper Tariff Protection -- Market Talk

11 aug 2025, 17:28 UTC

Marktinformatie

Crossborder Trade Tensions Accelerate Softness in Canada Rents -- Market Talk

11 aug 2025, 17:16 UTC

Marktinformatie

Commodity Longs Fall to 11-Month Low -- Market Talk

11 aug 2025, 16:42 UTC

Acquisities, Fusies, Overnames

Adobe Stock Gets a Downgrade. 'AI Is Eating Software,' Analyst Says. -- Barrons.com

11 aug 2025, 16:27 UTC

Acquisities, Fusies, Overnames

BBVA Says Sabadell Offer Remains in Effect

11 aug 2025, 16:26 UTC

Acquisities, Fusies, Overnames

BBVA Previously Said It Won't Withdraw Offer to Buy Sabadell

11 aug 2025, 16:25 UTC

Acquisities, Fusies, Overnames

Banco de Sabadell Announced TSB Sale on July 1

11 aug 2025, 16:25 UTC

Acquisities, Fusies, Overnames

Banco de Sabadell Shareholders Approved TSB Unit Sale on Aug 6

Peer Vergelijking

Prijswijziging

Erasca Inc Prognose

Koersdoel

By TipRanks

203.57% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 4.25 USD  203.57%

Hoogste 6 USD

Laagste 3 USD

Gebaseerd op 4 Wall Street-analisten die 12-maands prijsdoelen bieden voor Erasca Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

4 ratings

4

Buy

0

Hold

0

Sell

Technische score

By Trading Central

1.39 / 1.44Steun & Weerstand

Korte Termijn

Bearish Evidence

Gemiddeld Termijn

Weak Bearish Evidence

Lange Termijn

Very Strong Bearish Evidence

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Erasca Inc

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.